96964-41-9

Upstream product

• 57598-33-1 2-(2-methoxyphenyl)-4,4-dimethyl-2-oxazoline 
• 15890-72-9 laurylmagnesium bromide 
• 143-15-7 1-dodecylbromide 

Relevant academic research and scientific papers

Leukotriene antagonists

Leukotriene antagonist thiadiazoles have been prepared.

LEUKOTRIENE ANTAGONISTS CONTAINING TETRAZOLYL GROUPS

This invention relates to alkanoic acid compounds having phenyl and heteroarylthio substituents which are useful as leukotriene antagonists and pharmaceutical compositions containing such compounds. This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.

ESTER PRODRUGS

This invention relates to ester prodrugs for alkanoic acid compounds useful as leukotriene antagonists, and pharmaceutical compositions containing such ester prodrug compounds. This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.

Leukotriene antagonists

This invention relates to alkanoic acid compounds having phenyl and heteroarylthio substituents which are useful as leukotriene antagonists, pharmaceutical compositions containing such compounds, and methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.

Leukotriene antagonists

This invention relates to alkanoic acid compounds having phenyl and thio substituents which are useful as leukotriene antagonists and pharmaceutical compositions containing such compounds. This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.

Leukotriene antagonists

A method for inhibiting the effects of LTB4 comprises administration of an effective amount of a compound represented by the following structural formula (I) STR1 wherein m is 1 or 2; n is 1, 2 or 3; p is 0, 1, or 2; R' is hydrogen or methyl; R is phenyl substituted with A, R1 and R2 wherein R1 and R2 are independently selected from either (1) (S)a --(CH2)b --(T)c --B wherein a is 0 or 1; b is 5 to 12; c is 0 or 1; S and T are independently sulfur, oxygen, or CH2 with the proviso that S or T are not sulfur when p is 1 or 2; and B is C1-4 alkyl, ethynyl, trifluoromethyl, or phenyl optionally monosubstituted with Br, Cl, CF3, C1-4 alkoxy, C1-4 alkyl, methylthio, or trifluoromethylthio; or (2) hydrogen bromo, chloro, methyl, trifluoromethyl, methoxy or nitro; and A is selected from (2) as defined above or a pharmaceutically acceptable salt thereof. Such methods are useful in the treatment of diseases in which LTB4 is a factor.

THIOPHENYL ALKANOIC ACIDS USEFUL AS LEUKOTRIENE ANTAGONISTS

This invention relates to alkanoic acid compounds having phenyl and thio substituents which are useful as leukotriene antagonists and pharmaceutical compositions containing such compounds. This invention also relates to treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.

LEUKOTRIENE ANTAGONIST

The compounds represented by the following structural formula (I) STR1 wherein m is 1 or 2; n is 1, 2 or 3; R' is hydrogen or methyl; R is a radical selected from the group consisting of: STR2 wherein R. sub.1 is C 8 to C 13 alkyl, C 7 to C 12 alkoxy, C 7 to C 12 thioalkyl, C 10 to C 12 1-alkynyl, 11-dodecynyl, 1-trans-dodecenyl, 5-(4-acetyl-3-hydroxy-2-propylphenoxypentoxy, 2(Z), 5(Z)-undecadienyloxy, phenyl-C 4 to C. sub.10 alkyl with the phenyl optionally mono substituted with bromo, chloro, trifluoromethyl, methoxy, methylthio or trifluoromethylthio, phenylthio-C 3 to C 9 alkyl with the phenyl optionally mono substituted with bromo, chloro, trifluoromethyl, methoxy, methylthio or trifluoromethylthio, phenyl-CH. dbd.CH--(CH 2) 2-8, phenyl-C 3 to C 9 alkoxy, trifluoromethyl-C 7 to C 12 alkyl, cyclohexyl-C 4 to C 10 alkyl or STR3 wherein each q is 0, 1, 2 or 3 but the sum of both q's does not exceed 3, and R 2 is hydrogen, bromo, chloro, methyl, trifluoromethyl, hydroxy, methoxy or nitro; or R 1 is hydrogen and R. sub.2 is C 8 to C 13 alkyl, C 7 to C 12 alkoxy, C 7 to C 12 thioalkyl, C 10 to C. sub.12 1-alkynyl, 11-dodecynyl, 1-trans-dodecenyl, 5-(4-acetyl-3-hydroxy-2-propylphenoxy(pentoxy, 2(Z), 5(Z)-undecadienyloxy, phenyl-C 4 to C. sub.10 alkyl with the phenyl optionally mono substituted with bromo, chloro, trifluoromethyl, methoxy, methylthio or trifluoromethylthio, phenylthio-C 3 to C 9 alkyl with the phenyl optionally mono substituted with bromo, chloro, trifluoromethyl, methoxy, methylthio or trifluoromethylthio, phenyl-CH. dbd.CH--(CH 2) 2-8, phenyl-C 3 to C 9 alkoxy, trifluoromethyl-C 7 to C 12 alkyl, cyclohexyl-C 4 to C 10 alkyl or STR4 wherein each q is 0, 1, 2 or 3 but the sum of both q's does not exceed 3, and p is 0 or 1, with the proviso that R is not a thiophene radical and any of R 1 and R. sub.2 above are not thioalkyl or phenylthioalkyl when p is 1; and pharmaceutically acceptable salts thereof have been found to be leukotriene antagonists and useful in the treatment of diseases in which leukotrienes are a factor, such as asthma.